ESTRADIOL AND NORGESTIMATE
Clinical safety rating: avoid
Inducers of CYP450 enzymes (eg carbamazepine) may decrease estrogen levels Increases risk of thromboembolic disorders and endometrial cancer.
Estradiol is an estrogen that binds to estrogen receptors, modulating gene expression and exerting effects on reproductive tissues, bone, and cardiovascular system. Norgestimate is a progestin that acts as a partial agonist at progesterone receptors, suppressing gonadotropin secretion and altering cervical mucus and endometrial lining to prevent pregnancy.
| Metabolism | Estradiol is metabolized primarily in the liver via CYP3A4 to estrone and estriol, followed by glucuronidation and sulfation. Norgestimate is rapidly metabolized to norelgestromin and levonorgestrel via first-pass metabolism, with further metabolism by CYP3A4 and CYP2C9. |
| Excretion | Estradiol: primarily renal (50-80% as glucuronide and sulfate conjugates), fecal (10-20%). Norgestimate: metabolites excreted renally (55-65%) and fecally (30-40%). |
| Half-life | Estradiol: terminal half-life ~12-14 hours; Norgestimate: norelgestromin terminal half-life ~28 hours, norgestrel ~25 hours. Clinical context: steady-state achieved within 5-7 days. |
| Protein binding | Estradiol: 96-98% bound to sex hormone-binding globulin (SHBG) and albumin. Norelgestromin: 99% bound to SHBG and albumin. |
| Volume of Distribution | Estradiol: Vd ~1.2 L/kg. Norelgestromin: Vd ~2.5 L/kg. Clinical meaning: extensive tissue distribution. |
| Bioavailability | Transdermal estradiol: ~5-10% (due to first-pass metabolism; absolute bioavailability not well defined). Oral estradiol: <5% (extensive first-pass metabolism). Norgestimate: oral bioavailability >90% (norelgestromin). |
| Onset of Action | Transdermal: estradiol absorption detectable within 4-8 hours, clinical effects (e.g., vasomotor symptom relief) within 2-4 weeks. Oral: peak levels in 1-2 hours, clinical effects in 2-4 weeks. |
| Duration of Action | Transdermal patch: 7 days (replaced weekly). Oral: 24 hours (daily dosing). Clinical notes: continuous estrogen and progestin exposure. |
Estradiol 1 mg and norgestimate 0.18/0.215/0.25 mg orally once daily for the first 28-day cycle, with the norgimate dose titrated: 0.18 mg on days 1–7, 0.215 mg on days 8–14, and 0.25 mg on days 15–21, followed by placebo on days 22–28.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Not studied in severe impairment or dialysis; use with caution. |
| Liver impairment | Contraindicated in acute hepatic disease or Child-Pugh Class B or C cirrhosis. For mild hepatic impairment (Child-Pugh Class A), no specific dose adjustment available; use with caution. |
| Pediatric use | Not indicated for use in premenopausal pediatric patients. Safety and efficacy not established in children. |
| Geriatric use | No specific dose adjustment recommended for elderly patients >65 years, but use the lowest effective dose and consider increased risk of adverse effects such as cardiovascular events and dementia. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Inducers of CYP450 enzymes (eg carbamazepine) may decrease estrogen levels Increases risk of thromboembolic disorders and endometrial cancer.
| FDA category | Positive |
| Breastfeeding | Estradiol and norgestimate are excreted into human breast milk in small amounts. The milk-to-plasma ratio for estradiol is approximately 0.25-0.40. Combined hormonal contraceptives may reduce milk production and alter milk composition, particularly in the early postpartum period. Use is generally not recommended until weaning or after complete establishment of lactation. Alternative contraception is advised. |
| Teratogenic Risk |
■ FDA Black Box Warning
Cigarette smoking increases the risk of serious cardiovascular events from combination hormonal contraceptive use. This risk increases with age, especially in women over 35 years of age, and with the number of cigarettes smoked. Women who use combination hormonal contraceptives should be strongly advised not to smoke.
| Common Effects | osteoporosis prevention |
| Serious Effects |
["Known or suspected pregnancy","Current or past thrombophlebitis or thromboembolic disorders","History of deep vein thrombosis or pulmonary embolism","Active or recent arterial thromboembolic disease (e.g., stroke, myocardial infarction)","Known or suspected breast cancer","Known or suspected estrogen-dependent neoplasia","Undiagnosed abnormal genital bleeding","Known hepatic impairment or disease (e.g., acute hepatitis, decompensated cirrhosis, liver tumors)","Hypersensitivity to estradiol or norgestimate","Heavy smoking (≥15 cigarettes/day) in women over 35 years of age"]
| Precautions | ["Thromboembolic disorders: increased risk of venous thromboembolism and arterial thrombosis","Cardiovascular disease: increased risk of myocardial infarction and stroke, especially in smokers and women with hypertension","Carcinoma of the breast and reproductive organs: estrogens may increase risk","Hepatic effects: jaundice, cholestasis, liver tumors","Gallbladder disease: increased risk","Ocular changes: retinal thrombosis, vision loss","Elevated blood pressure","Hypertriglyceridemia","Glucose tolerance changes","Fluid retention","Depression","Unscheduled bleeding"] |
Loading safety data…
| First trimester: Combination estrogen-progestin oral contraceptives are not recommended during pregnancy due to a potential but low risk of congenital anomalies; some studies suggest a slight increase in cardiovascular defects and limb reduction defects. Second and third trimesters: Use is contraindicated as it may cause fetal harm; exposure has been associated with masculinization of female fetuses (due to progestin) and possible cardiovascular and genitourinary tract anomalies. Withdrawal of therapy is advised if pregnancy is detected. |
| Fetal Monitoring | Routine pregnancy testing if pregnancy is suspected. No specific fetal monitoring required beyond standard prenatal care. Monitor for signs of thrombotic events, hypertension, and hepatic dysfunction. Inadvertent use during pregnancy does not typically require invasive fetal monitoring. |
| Fertility Effects | This combination estrogen-progestin acts primarily by suppressing ovulation. Upon discontinuation, ovulation typically resumes within 1-3 months, but transient delay in return to fertility may occur. No permanent effects on fertility have been documented. Long-term use does not impair future fecundity. |